Neoadjuvant FOLFIRINOX treatment for borderline resectable pancreatic ductal adenocarcinoma: The pathological implications

Introduction: The ACCORD trial has shown FOLFIRINOX to be effective in metastatic pancreatic adenocarcinoma (PDAC). It is a rational choice of chemotherapy to use within a neoadjuvant context as a prelude to resection of resectable or borderline resectable PDAC. This study was to determine the surgical and clinicopathologic outcomes of pancreatic resections after neoadjuvant FOLFIRINOX therapy. Methods: Clinicopathologic data for 32patients...